Tuesday, October 28, 2008 6:27:42 PM
Newton, Mass.-based Clinical Data (Nasdaq: CLDA) said the acquisition of Avalon Pharmaceuticals (Nasdaq: AVRX) in Germantown, Md., will help expand its cancer business with technology to help identify both new diagnostics and treatments.
The price is based on the 15-day volume weighted average price of $12.49 for Clinical Data’s common stock through Oct. 27.
Clinical Data buys rival for $10M in stock
The agreement also entailed Clinical Data completing a private placement of nearly 3.4 million shares of Avalon’s common stock. Clinical Data also loaned Avalon $3 million, and paid Avalon $1 million in exchange for a global, exclusive license to that company’s technology for drug and biomarker discovery. A biomarker can indicate the activity or likelihood of a certain disease such as cancer.
Late in September, Clinical Data negotiated a $25 million private placement to handle day-to-day working capital.
The company is developing new biotechnology treatments and also tests to help predict drug safety and effectiveness.
Clinical Data’s headquarters will remain in Newton. The company employs about 300 people around the world.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM